


CLAIMS

1. Formula (I) compounds:



I

where:

A is CH; alkanylidene with 2 to 4 carbon atoms,
 particularly CH₂-CH; alkenylidene with 2 to 4 carbon
 atoms, particularly CH=C;

Ar is monocyclic or bicyclic C₆-C₁₀ aryl or heteroaryl,
 containing one or more heteroatoms selected from the
 group consisting of nitrogen, oxygen and sulphur, possibly
 substituted by halogens, NO₂, OH, C₁-C₄ alkyl and alkoxy,
 said alkyl and alkoxy possibly substituted by at least one
 halogen; monocyclic, bicyclic or tricyclic arylalkyl or
 heteroarylalkyl containing one or more heteroatoms
 selected from the group consisting of nitrogen, oxygen and
 sulphur, where the alkyl residue contains from 1 to 3
 carbon atoms, said arylalkyl or heteroarylalkyl possibly
 substituted by halogens, NO₂, OH, C₁-C₄ alkyl and alkoxy,

said alkyl and alkoxy possibly substituted by at least one halogen;

f is the number 0 or 1;

h is the number 0 or 1;

5 m is a whole number from 0 to 3;

n is the number 0 or 1 and if n is 0, R₁ is absent, and COY is directly bound to benzene);

Q and Z, which may be the same or different, are selected from the group consisting of NH, O, S, NHC(O)O, NHC(O)NH, NHC(O)S, OC(O)NH, S(CO)NH, C(O)NH, and NHC(O);

10

R is selected from R₂, OR₂;

R₁ is selected from H, COW, SO₃⁻, OR₃, =O, CN, NH₂, NHCO(C₆-C₁₀)Ar, where Ar may possibly be substituted by halogens, NO₂, OH, C₁-C₄ alkyl and alkoxy, said alkyl and alkoxy possibly substituted by at least one halogen;

15

R₂ is selected from H, straight or branched C₁-C₄ alkyl, possibly substituted by at least one halogen;

R₃ is selected from H, straight or branched C₁-C₄ alkyl, possibly substituted by at least one halogen, (C₆-C₁₀)ArCH₂, where Ar is possibly substituted by halogens, NO₂, OH, C₁-C₄ alkyl and alkoxy, said alkyl and alkoxy possibly substituted by at least one halogen;

20


W is selected from OH, OR₄, NH₂;

R₄ is straight or branched C₁-C₄ alkyl;

Y is selected from OH, OR₅, NH₂;

R₅ is straight or branched C₁-C₄ alkyl;

or A, COY and R₁ together form a cycle of the type:



5

their pharmacologically acceptable salts, racemic mixtures, individual enantiomers, geometric isomers or stereoisomers, and tautomers.

2. Compounds according to claim 1, in which Ar is a heteroaryl, preferably containing nitrogen as the heteroatom, and preferably f is 0, m is 1 or 2, Q is oxygen, and R is hydrogen.

10

3. Compounds according to claim 1, in which Ar is an aryl, possibly substituted by one or more halogen atoms, alkyl, alkoxy or lower haloalkyl, nitro, mono- or di-alkylamine, and preferably f is 0, m is 0, 1 or 2, Q is oxygen or HNC(O)O, and R is hydrogen.

15

4. Compounds according to one of claims 1-3, where R₁ is COW.

5. Compound according to claim 1, selected from the group consisting of:

- i. Diethyl 4-[2-(1-indolyl)ethoxy]benzylidenemalonate;
- ii. Diethyl 4-[2-(1-indolyl)ethoxy]benzylmalonate;
- 5 iii. Dimethyl 4-[2-(1-indolyl)ethoxy]benzylidenemalonate;
- iv. Dimethyl 4-[2-(1-indolyl)ethoxy]benzylmalonate;
- v. 4-[2-(1-indolyl)ethoxy]benzylmalonic acid;
- vi. Methyl (2S)-amino-2-[4-[2-(1-indolyl)ethoxy]phenyl]-acetate;
- 10 vii. Methyl 4-[2-(1-indolyl)ethoxy]benzoate;
- viii. Methyl 3-[4-[2-(1-indolyl)ethoxy]phenyl]propanoate;
- ix. Methyl 2-[4-[2-(1-indolyl)ethoxy]phenyl]acetate;
- x. Methyl 2-sulpho-2-[4-[2-(1-indolyl)ethoxy]phenyl]acetate sodium salt;
- 15 xi. Methyl (S)-2-benzoylamino-2-[4-[2-(1-indolyl)ethoxy]-phenyl]acetate;
- xii. Methyl 2-hydroxy-3-[4-[2-(1-indolyl)ethoxy]phenyl]-propanoate;
- xiii. Dimethyl 4-[2-[4-(dimethylamino)phenyl]ethoxy]benzylmalonate;
- 20

- xiv. Methyl 3-[4-[2-(1-indolyl)ethoxy]phenyl]-2-cyano-propionate;
- xv. Methyl 3-[4-[2-(1-indolyl)ethoxy]phenyl]-2-cyano-propionate;
- 5 xvi. Dimethyl 4-[2-(3-indolyl)ethoxy]benzylidenemalonate;
- xvii. Dimethyl 4-[2-(1-naphthyl)ethoxy]benzylmalonate;
- xviii. Dimethyl 4-[2-(2-pyridyl)ethoxy]benzylmalonate;
- xix. Dimethyl 4-[2-(4-chlorophenyl)ethoxy]benzylmalonate;
- xx. 5-[4-[2-(4-chlorophenyl)ethoxy]phenylmethylene]-thiazolidine-2,4-dione;
- 10 xxi. 5-[4-[2-(4-chlorophenyl)ethoxy]phenylmethyl]thiazolidine-2,4-dione;
- xxii. Dimethyl 3-[2-(4-chlorophenyl)ethoxy]benzylmalonate;
- xxiii. Dimethyl 3-[2-(phenyl)ethoxy]benzylmalonate;
- 15 xxiv. Dimethyl 3-[N-(4-trifluoromethylbenzyl)carbamoyl]-4-methoxybenzylmalonate;
- xxv. Dimethyl 4-methoxy-3-[2-(4-chlorophenyl)ethoxy]benzylmalonate:
- xxvi. Dimethyl 3-(2-phenylethoxy)-4-methoxy benzylmalonate;
- 20 xxvii. Dimethyl 4-[2-(4-methoxyphenyl)ethoxy]benzylmalonate;

xxviii. Dimethyl 4-[3-(4-methoxyphenyl)propyloxy]benzyl-mal-
lonate;

xxix. Dimethyl 4-[2-(2-naphthyl)ethoxy]benzylmalonate;

xxx. (2S)-2-benzoylamino-3-[4-[(4-methoxybenzyl)-carbamoyl-
5]oxyphenyl]ethyl propanoate;

xxxi. Dimethyl 4-[[[(4-methoxybenzyl)carbamoyl]oxy]benzyl-ma-
lonate;

xxxii. Dimethyl 4-[[[(4-trifluorotolyl)carbamoyl]oxy]benzyl-malo-
nate;

10 xxxiii. Dimethyl 4-[[[(2,4-dichlorophenyl)carbamoyl]oxy]benzyl-
malonate;

xxxiv. Dimethyl 4-[[[(4-chlorophenyl)carbamoyl]oxy]benzyl-ma-
lonate;

15 xxxv. Dimethyl 4-[2-(pyridinio)ethoxy]benzylmalonate methane-
sulphonate;

xxxvi. Dimethyl 4-[[[(4-nitrophenyl)carbamoyl]oxy]benzyl-ma-
lonate;

xxxvii. Dimethyl 3-[[[(4-methoxybenzyl)carbamoyl]oxy]benzyl-
malonate;

20 xxxviii. Dimethyl 3-[[[(4-butylphenyl)carbamoyl]oxy]benzyl-ma-
lonate;

xxxix. Dimethyl 4-[[[(4-butylphenyl)carbamoyl]oxy]benzyl-mal-
lonate;

xl. Dimethyl 3-[[[(4-chlorophenyl)carbamoyl]oxy]benzyl-malo-
nate;

5 xli. (Z)-2-ethoxy-3-[4-[2-(4-chloro-phenyl)ethoxy]-phenyl]
ethyl propenoate;

xlii. (E)-2-ethoxy-3-[4-[2-(4-chloro-phenyl)ethoxy]-phenyl]ethyl
propenoate;

xliii. (R,S)-2-ethoxy-3-[4-[2-(phenyl)ethoxy]phenyl]ethyl propa-
10 noate;

xliv. (R,S)-2-ethoxy-3-[4-[2-(4-chloro-phenyl)ethoxy]-phenyl-
]methyl propanoate;

xlvi. Dimethyl 4-[2-(2,3-dimethyl-1-indolyl)ethoxy]benzyl-ma-
lonate.

15 6. Compounds according to claims 1-5 as medicines.

7. Pharmaceutical compositions containing at least one
compound according to claims 1-5 in mixtures with
pharmaceutically acceptable vehicles and/or excipients.

20 8. Use of the compounds according to claims 1-5 for the
preparation of a medicine with serum glucose and serum
lipid lowering activity.

9. Use of the compounds according to claims 1-5 for the preparation of a medicine for the prophylaxis and treatment of diabetes, particularly type 2, and its complications, Syndrome X, the various forms of insulin resistance and hyperlipdaemias.